The top 100 ven­ture in­vestors in bio­phar­ma to­day. Who's stay­ing at the deals ta­ble?

Re­mem­ber how good 2020 was for biotech ven­ture num­bers? Now hold that thought.

Div­ing in­to the num­bers for life sci­ence ven­ture in­vestors last year, Deal­For­ma’s Chris Doko­ma­ji­lar tracked a dra­mat­ic down­turn in 2022, set­ting the stage for a new nor­mal that puts health­care back at lev­els reg­is­tered in 2019 and 2020.

But bio­phar­ma was sin­gled out for some rough han­dling once you break them out of the pack. In his an­nu­al look at the top 100 in­vestors in biotech, Doko­ma­ji­lar found that close to $20 bil­lion of the $51 bil­lion in life sci­ences in­vest­ments tracked last year were di­rect­ed at plat­forms and ther­a­peu­tics.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE